MedTrace Logo

Early Prostate Cancer: Predicting Treatment Response

NCT03770351 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 693

Last updated 2021-04-09

No results posted yet for this study

Summary

This study will replicate/validate the risk prediction model developed for the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study in a more diverse patient population to assess generalizability of the model as well as evaluate the relative contribution of the Decipher Prostate Cancer Test and ProstateNext Test from Ambry Genetics, to the risk prediction model for estimating treatment outcomes, and thereby improve personalization of treatment options.

Conditions

Sponsors & Collaborators

  • University of California, Los Angeles

    collaborator OTHER

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • VA Medical Center-West Los Angeles

    collaborator FED

  • VA Long Beach Healthcare System

    collaborator FED

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Sheldon Greenfield · University of California, Irvine

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-07-31
Completion
2021-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03770351 on ClinicalTrials.gov